Start Submission Become a Reviewer

Reading: The new oral antiviral agents for COVID-19

Download

A- A+
Alt. Display

Review Articles

The new oral antiviral agents for COVID-19

Authors:

S.L. Seneviratne ,

Royal Free Hospital and University College London, UK; Consultant Physician Nawaloka Hospital Research and Education Foundation, Nawaloka Hospitals PLC, LK
About S.L.
Professor in Immunology, Institute of Immunity and Transplantation
X close

C. Dalugama,

Faculty of Medicine, University of Peradeniya, LK
About C.
Consultant Physician (Acting) and lecturer in medicine, Department of Medicine
X close

P. Madanayake,

John Radcliffe Hospital Oxford, GB
About P.
Specialist Registrar in Acute Medicine, Department of Acute Medicine
X close

B. Samaraweera,

Liberty Publishers Private Limited, LK
About B.
Research Fellow
X close

J. Kariyawasam,

Sir John Kotalawala Defence University, Ratmalana, LK
About J.
Scientist, Biomedical Laboratory 2
X close

V. Abeysuriya

Royal Free Hospital and University College London, GB
About V.
Medical Officer, Institute of Immunity and Transplantation
X close

Abstract

Coronavirus Disease-2019 (COVID-19), has so far affected more than 275 million individuals globally and caused over 5.3 million deaths. With an effective vaccine, disease and infection could be prevented, whereas with antivirals and monoclonal antibodies, disease progression could be mitigated. In recent months, there has been much interest in evaluating the use of oral antivirals, in those having mild disease and associated risk factors for disease progression (such as multiple comorbidities), in view of preventing severe COVID-19. Our review discusses the known properties and identified effectiveness of three oral antiviral drugs (Molnupiravir, Paxlovid and AT-527) for COVID-19 (as at end of December 2021) and explores their potential role in mitigating the ill effects of the on-going COVID-19 pandemic.  

How to Cite: Seneviratne SL, Dalugama C, Madanayake P, Samaraweera B, Kariyawasam J, Abeysuriya V. The new oral antiviral agents for COVID-19. Asian Journal of Internal Medicine. 2022;1(1):50–9. DOI: http://doi.org/10.4038/ajim.v1i1.31
20
Downloads
Published on 31 Jan 2022.
Peer Reviewed

Downloads

  • PDF (EN)

    comments powered by Disqus